Teladoc Health, Inc.

BMV:TDOC * Stock Report

Market Cap: Mex$32.3b

Teladoc Health Valuation

Is TDOC * undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of TDOC * when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: TDOC * (MX$183) is trading below our estimate of fair value (MX$423.48)

Significantly Below Fair Value: TDOC * is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for TDOC *?

Key metric: As TDOC * is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for TDOC *. This is calculated by dividing TDOC *'s market cap by their current revenue.
What is TDOC *'s PS Ratio?
PS Ratio0.6x
SalesUS$2.59b
Market CapUS$1.59b

Price to Sales Ratio vs Peers

How does TDOC *'s PS Ratio compare to its peers?

The above table shows the PS ratio for TDOC * vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average4.5x
NXGN NextGen Healthcare
2.3x6.7%US$1.6b
CERT Certara
4.3x9.6%US$1.7b
EMIS EMIS Group
7x4.8%UK£1.2b
NXU Nexus
4.5x9.8%€1.2b
TDOC * Teladoc Health
0.6x0.8%Mex$1.6b

Price-To-Sales vs Peers: TDOC * is good value based on its Price-To-Sales Ratio (0.6x) compared to the peer average (4.4x).

Price to Sales Ratio vs Industry

How does TDOC *'s PS Ratio compare vs other companies in the Global Healthcare Services Industry?

44 CompaniesPrice / SalesEstimated GrowthMarket Cap
Industry Avg.n/a0%
TDOC * Teladoc Health
 0.6x0.8%US$1.59b
No. of Companies43PS03.26.49.612.816+
44 CompaniesEstimated GrowthMarket Cap
Industry Avg.n/a0%
TDOC * Teladoc Health
 0.6x81.4%US$1.59b
No more companies

Price-To-Sales vs Industry: TDOC * is good value based on its Price-To-Sales Ratio (0.6x) compared to the Global Healthcare Services industry average (3.1x).

Price to Sales Ratio vs Fair Ratio

What is TDOC *'s PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

TDOC * PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio0.6x
Fair PS Ration/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate TDOC *'s Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst TDOC * forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentMex$183.00
Mex$216.51
+18.3%
16.0%Mex$285.44Mex$163.11n/a21
Nov ’25Mex$184.00
Mex$208.17
+13.1%
15.5%Mex$280.22Mex$160.13n/a20
Oct ’25Mex$180.00
Mex$191.54
+6.4%
20.3%Mex$327.25Mex$154.00n/a20
Sep ’25Mex$144.49
Mex$186.23
+28.9%
21.0%Mex$324.31Mex$152.61n/a21
Aug ’25Mex$159.63
Mex$232.42
+45.6%
36.9%Mex$469.30Mex$150.18n/a21
Jul ’25Mex$173.00
Mex$305.08
+76.3%
24.0%Mex$461.58Mex$184.63n/a21
Jun ’25Mex$190.18
Mex$284.38
+49.5%
22.5%Mex$424.14Mex$169.66n/a21
May ’25Mex$221.41
Mex$295.76
+33.6%
19.1%Mex$425.50Mex$204.24n/a22
Apr ’25Mex$251.99
Mex$345.18
+37.0%
17.8%Mex$474.63Mex$271.21n/a22
Mar ’25Mex$256.00
Mex$349.29
+36.4%
17.7%Mex$476.52Mex$272.30n/a21
Feb ’25Mex$337.00
Mex$390.72
+15.9%
18.7%Mex$576.96Mex$271.51n/a20
Jan ’25Mex$367.00
Mex$392.73
+7.0%
20.8%Mex$585.65Mex$275.60n/a19
Dec ’24Mex$325.00
Mex$392.73
+20.8%
20.8%Mex$585.65Mex$275.60n/a19
Nov ’24Mex$299.90
Mex$424.36
+41.5%
21.9%Mex$613.01Mex$288.48Mex$184.0019
Oct ’24Mex$323.00
Mex$522.41
+61.7%
16.1%Mex$707.34Mex$353.67Mex$180.0019
Sep ’24Mex$390.00
Mex$514.73
+32.0%
13.8%Mex$683.82Mex$427.39Mex$144.4921
Aug ’24Mex$466.42
Mex$503.37
+7.9%
14.0%Mex$669.78Mex$418.61Mex$159.6321
Jul ’24Mex$425.00
Mex$519.91
+22.3%
12.6%Mex$685.22Mex$428.27Mex$173.0022
Jun ’24Mex$420.00
Mex$545.01
+29.8%
12.5%Mex$717.22Mex$448.26Mex$190.1822
May ’24Mex$476.00
Mex$544.87
+14.5%
13.0%Mex$719.20Mex$413.54Mex$221.4122
Apr ’24Mex$446.00
Mex$556.66
+24.8%
13.8%Mex$740.21Mex$425.62Mex$251.9921
Mar ’24Mex$520.00
Mex$568.73
+9.4%
13.2%Mex$731.94Mex$457.46Mex$256.0021
Feb ’24Mex$572.00
Mex$604.31
+5.6%
14.9%Mex$844.17Mex$450.22Mex$337.0022
Jan ’24Mex$443.00
Mex$644.73
+45.5%
14.6%Mex$883.76Mex$471.34Mex$367.0024
Dec ’23Mex$515.00
Mex$633.85
+23.1%
14.6%Mex$865.55Mex$461.63Mex$325.0024
Nov ’23Mex$571.11
Mex$651.50
+14.1%
14.6%Mex$887.40Mex$473.28Mex$299.9024

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

ZimVie

US$186.2m

Develops, manufactures, and markets a portfolio of products and solutions designed to treat various spine pathologies, and support dental tooth replacement and restoration procedures worldwide.

ZIMV *

US$230.00

7D

0%

1Y

n/a

M3

JP¥880.0b

Provides medical-related services primarily to physicians and other healthcare professionals through Internet.

2413 N

JP¥183.50

7D

0%

1Y

n/a

DaVita

US$12.7b

Provides kidney dialysis services for patients suffering from chronic kidney failure in the United States.

DVA *

US$3,113.21

7D

0%

1Y

n/a